An increase in circulating B cell-activating factor in childhood-onset ocular myasthenia gravis

Background: Myasthenia gravis is a B cell-mediated autoimmune disorder. The pathophysiology of childhood-onset ocular Myasthenia gravis remains unclear. We investigated serum B cell-activating factor levels and other immunological parameters in child patients with ocular Myasthenia gravis.

Methods: Blood samples were obtained from 9 children with ocular Myasthenia gravis and 20 age-matched controls. We assayed serum concentrations of B cell-activating factor, anti-acetylcholine receptor antibody titers, 7 types of cytokines (interleukins-2, -4, -6, -10, and -17A; interferon-γ; tumor necrosis factor-α) as well as the percentages of peripheral blood CD4+, CD8+, and CD19+ cells.

Results: Serum B cell-activating factor levels were significantly higher before immunosuppressive therapy in patients with childhood-onset ocular Myasthenia gravis than in controls and decreased after immunosuppressive therapy. A significant positive correlation was observed between serum B cell-activating factor levels and anti-acetylcholine receptor antibody titers in patients with Myasthenia gravis. Serum B cell-activating factor concentrations did not correlate with the percentages of CD4+, CD8+, and CD19+ cells or the CD4+/CD8+ ratio. No significant differences were observed in the levels of the 7 different types of cytokines examined, including interleukin-17A, between preimmunosuppressive therapy Myasthenia gravis patients and controls.

Conclusions: Circulating B cell-activating factor may play a key role in the pathophysiology of childhood-onset ocular Myasthenia gravis.